Page 2240 - Williams Hematology ( PDFDrive )

2214 Part XII: Hemostasis and Thrombosis Chapter 129: Disseminated Intravascular Coagulation 2215

48. Versteeg HH, Peppelenbosch MP, Spek CA: The pleiotropic effects of tissue factor: A 82. Lay AJ, Donahue D, Tsai MJ, et al: Acute inflammation is exacerbated in mice geneti-
possible role for factor VIIa-induced intracellular signalling? Thromb Haemost 86:1353, cally predisposed to a severe protein C deficiency. Blood 109:1984, 2007.
2001. 83. Feistritzer C, Sturn DH, Kaneider NC, et al: Endothelial protein C receptor-depen-
49. Levi M, de Jonge E, van der Poll T: Rationale for restoration of physiological anticoag- dent inhibition of human eosinophil chemotaxis by protein C. J Allergy Clin Immunol
ulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit 112:375, 2003.
Care Med 29:S90, 2001. 84. Sturn DH, Kaneider NC, Feistritzer C, et al: Expression and function of the endothelial
50. Szaba FM, Smiley ST: Roles for thrombin and fibrin(ogen) in cytokine/chemokine pro- protein C receptor in human neutrophils. Blood 102:1499, 2003.
duction and macrophage adhesion in vivo. Blood 99:1053, 2002. 85. Hoffmann JN, Vollmar B, Laschke MW, et al: Microhemodynamic and cellular mech-
51. Levi M, van der Poll T: The role of natural anticoagulants in the pathogenesis and man- anisms of activated protein C action during endotoxemia. Crit Care Med 32:1011,
agement of systemic activation of coagulation and inflammation in critically ill patients. 2004.
Semin Thromb Hemost 34:459, 2008. 86. Nick JA, Coldren CD, Geraci MW, et al: Recombinant human activated protein C
52. Levi M: Antithrombin in sepsis revisited. Crit Care 9:624, 2005. reduces human endotoxin-induced pulmonary inflammation via inhibition of neu-
53. Levi M, van der Poll T: Two-way interactions between inflammation and coagulation. trophil chemotaxis. Blood 104:3878, 2004.
Trends Cardiovasc Med 15:254, 2005. 87. Shimizu S, Gabazza EC, Taguchi O, et al: Activated protein C inhibits the expression of
54. Kobayashi M, Shimada K, Ozawa T: Human recombinant interleukin-1 beta- and platelet-derived growth factor in the lung. Am J Respir Crit Care Med 167:1416, 2003.
tumor necrosis factor alpha-mediated suppression of heparin-like compounds on cul- 88. Zeng W, Matter WF, Yan SB, et al: Effect of drotrecogin alfa (activated) on human endo-
tured porcine aortic endothelial cells. J Cell Physiol 144:383, 1990. thelial cell permeability and Rho kinase signaling. Crit Care Med 32:S302, 2004.
55. Levi M, van der Poll T: Recombinant human activated protein C: Current insights into 89. Feistritzer C, Riewald M: Endothelial barrier protection by activated protein C through
its mechanism of action. Crit Care 11 Suppl 5:S3, 2007. PAR1-dependent sphingosine 1-phosphate receptor-1 cross activation. Blood 105:3178,
56. Esmon CT: Role of coagulation inhibitors in inflammation. Thromb Haemost 86:51, 2005.
2001. 90. Finigan JH, Dudek SM, Singleton PA, et al: Activated protein C mediates novel lung
57. Esmon CT: The regulation of natural anticoagulant pathways. Science 235:1348, endothelial barrier enhancement: Role of sphingosine 1-phosphate receptor transacti-
1987. vation. J Biol Chem 280:17286, 2005.
58. Esmon CT: The endothelial cell protein C receptor. Thromb Haemost 83:639, 2000. 91. Cheng T, Liu D, Griffin JH, et al: Activated protein C blocks p53-mediated apoptosis in
59. Mesters RM, Helterbrand J, Utterback BG, et al: Prognostic value of protein C concen- ischemic human brain endothelium and is neuroprotective. Nat Med 9:338, 2003.
trations in neutropenic patients at high risk of severe septic complications. Crit Care 92. Riewald M, Petrovan RJ, Donner A, et al: Activation of endothelial cell protease acti-
Med 28:2209, 2000. vated receptor 1 by the protein C pathway. Science 296:1880, 2002.
60. Vary TC, Kimball SR: Regulation of hepatic protein synthesis in chronic inflammation 93. Mosnier LO, Griffin JH: Inhibition of staurosporine-induced apoptosis of endothelial
and sepsis. Am J Physiol 262:C445, 1992. cells by activated protein C requires protease activated receptor-1 and endothelial cell
61. Eckle I, Seitz R, Egbring R, et al: Protein C degradation in vitro by neutrophil elastase. protein C receptor. Biochem J 373:65, 2003.
Biol Chem Hoppe Seyler 372:1007, 1991. 94. Mosnier LO, Zlokovic BV, Griffin JH: The cytoprotective protein C pathway. Blood
62. Nawroth PP, Stern DM: Modulation of endothelial cell hemostatic properties by tumor 109:3161, 2007.
necrosis factor. J Exp Med 163:740, 1986. 95. Biemond BJ, Levi M, ten Cate H, et al: Plasminogen activator and plasminogen acti-
63. Faust SN, Levin M, Harrison OB, et al: Dysfunction of endothelial protein C activation vator inhibitor I release during experimental endotoxaemia in chimpanzees: Effect of
in severe meningococcal sepsis. N Engl J Med 345:408, 2001. interventions in the cytokine and coagulation cascades. Clin Sci 88:587, 1995.
64. Taylor FB Jr, Dahlback B, Chang AC, et al: Role of free protein S and C4b binding pro- 96. Schleef RR, Bevilacqua MP, Sawdey M, et al: Cytokine activation of vascular endothe-
tein in regulating the coagulant response to Escherichia coli. Blood 86:2642, 1995. lium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator
65. Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S, et al: The endothelial cell protein C inhibitor. J Biol Chem 263:5797, 1988.
receptor aids in host defense against Escherichia coli sepsis. Blood 95:1680, 2000. 97. van Hinsbergh VW, Kooistra T, van den Berg EA, et al: Tumor necrosis factor increases
66. De Pont AC, Bakhtiari K, Hutten BA, et al: Endotoxaemia induces resistance to acti- the production of plasminogen activator inhibitor in human endothelial cells in vitro
vated protein C in healthy humans. Br J Haematol 134:213, 2006. and in rats in vivo. Blood 72:1467, 1988.
67. de Jonge E, Dekkers PE, Creasey AA, et al: Tissue factor pathway inhibitor (TFPI) 98. Asakura H, Ontachi Y, Mizutani T: An enhanced fibrinolysis prevents the development
dose-dependently inhibits coagulation activation without influencing the fibrinolytic of multiple organ failure in disseminated intravascular coagulation in spite of much
and cytokine response during human endotoxemia. Blood 95:1124, 2000. activation of blood coagulation. Crit Care Med 29:1164, 2001.
68. Creasey AA, Chang AC, Feigen L, et al: Tissue factor pathway inhibitor reduces mortal- 99. Yamamoto K, Loskutoff DJ: Fibrin deposition in tissues from endotoxin-treated mice
ity from Escherichia coli septic shock. J Clin Invest 91:2850, 1993. correlates with decreases in the expression of urokinase-type but not tissue-type plas-
69. Roemisch J, Gray E, Hoffmann JN, et al: Antithrombin: A new look at the actions of a minogen activator. J Clin Invest 97:2440, 1996.
serine protease inhibitor. Blood Coagul Fibrinolysis 13:657, 2002. 100. Nesheim M, Wang W, Boffa M, et al: Thrombin, thrombomodulin and TAFI in the
70. Opal SM: Interactions between coagulation and inflammation. Scand J Infect Dis molecular link between coagulation and fibrinolysis. Thromb Haemost 78:386, 1997.
35:545, 2003. 101. Salvemini D, Cuzzocrea S: Oxidative stress in septic shock and disseminated intravas-
71. Harada N, Okajima K, Kushimoto S, et al: Antithrombin reduces ischemia/reperfusion cular coagulation. Free Radic Biol Med 33:1173, 2002.
injury of rat liver by increasing the hepatic level of prostacyclin. Blood 93:157, 1999. 102. Asakura H, Okudaira M, Yoshida T: Induction of vasoactive substances differs in
72. Horie S, Ishii H, Kazama M: Heparin-like glycosaminoglycan is a receptor for antith- LPS-induced and TF-induced DIC models in rats. Thromb Haemost 88:663, 2002.
rombin III-dependent but not for thrombin-dependent prostacyclin production in 103. Levi M, Nieuwdorp M, van der Poll T, et al: Metabolic modulation of inflammation-in-
human endothelial cells. Thromb Res 59:895, 1990. duced activation of coagulation. Semin Thromb Hemost 34:26, 2008.
73. Mizutani A, Okajima K, Uchiba M, et al: Antithrombin reduces ischemia/reperfu- 104. Kjalke M, Silveira A, Hamsten A, et al: Plasma lipoproteins enhance tissue factor-inde-
sion-induced renal injury in rats by inhibiting leukocyte activation through promotion pendent factor VII activation. Arterioscler Thromb Vasc Biol 20:1835, 2000.
of prostacyclin production. Blood 101:3029, 2003. 105. van der Poll T, Coyle SM, Levi M, et al: Fat emulsion infusion potentiates coagulation
74. Uchiba M, Okajima K, Murakami K: Effects of various doses of antithrombin III on activation during human endotoxemia. Thromb Haemost 75:83, 1996.
endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. 106. Pajkrt D, Lerch PG, van der Poll T, et al: Differential effects of reconstituted high-den-
Thromb Res 89:233, 1998. sity lipoprotein on coagulation, fibrinolysis and platelet activation during human endo-
75. Esmon CT: New mechanisms for vascular control of inflammation mediated by natural toxemia. Thromb Haemost 77:303, 1997.
anticoagulant proteins. J Exp Med 196:561, 2002. 107. Birjmohun RS, van Leuven SI, Levels JH, et al: High-density lipoprotein attenuates
76. Okajima K: Regulation of inflammatory responses by natural anticoagulants. Immunol inflammation and coagulation response on endotoxin challenge in humans. Arterio-
Rev 184:258, 2001. scler Thromb Vasc Biol 27:1153, 2007.
77. Taylor FB Jr, Chang A, Esmon CT, et al: Protein C prevents the coagulopathic and lethal 108. Bisoendial RJ, Kastelein JJ, Peters SL, et al: Effects of CRP infusion on endothelial func-
effects of Escherichia coli infusion in the baboon. J Clin Invest 79:918, 1987. tion and coagulation in normocholesterolemic and hypercholesterolemic subjects. J
78. Hancock WW, Tsuchida A, Hau H, et al: The anticoagulants protein C and protein S Lipid Res 48:952, 2007.
display potent antiinflammatory and immunosuppressive effects relevant to transplant 109. Grant PJ: Diabetes mellitus as a prothrombotic condition. J Intern Med 262:157, 2007.
biology and therapy. Transplant Proc 24:2302, 1992. 110. Juhan-Vague I, Roul C, Alessi MC, et al: Increased plasminogen activator inhibitor
79. Hancock WW, Grey ST, Hau L, et al: Binding of activated protein C to a specific recep- activity in non insulin dependent diabetic patients—Relationship with plasma insulin.
tor on human mononuclear phagocytes inhibits intracellular calcium signaling and Thromb Haemost 61:370, 1989.
monocyte-dependent proliferative responses. Transplantation 60:1525, 1995. 111. Mansfield MW, Stickland MH, Grant PJ: PAI-1 concentrations in first-degree relatives
80. White B, Schmidt M, Murphy C, et al: Activated protein C inhibits lipopolysaccha- of patients with non-insulin-dependent diabetes: Metabolic and genetic associations.
ride-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour Thromb Haemost 77:357, 1997.
necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J 112. Samad F, Pandey M, Loskutoff DJ: Regulation of tissue factor gene expression in obe-
Haematol 110:130, 2000. sity. Blood 98:3353, 2001.
81. Levi M, Dorffler-Melly J, Reitsma PH, et al: Aggravation of endotoxin-induced dis- 113. Stegenga ME, van der Crabben SN, Levi M, et al: Hyperglycemia enhances coagulation
seminated intravascular coagulation and cytokine activation in heterozygous protein C and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis
deficient mice. Blood 101:4823, 2003. during human endotoxemia. Blood 112:82, 2008.

Kaushansky_chapter 129_p2199-2220.indd 2215 17/09/15 3:46 pm